Enteric Coated Pellets for Targeted Delivery

High-Quality Enteric-Coated Pellets for Advanced Drug Delivery Solutions

Our Enteric-Coated (EC) Pellets are designed to protect active pharmaceutical ingredients (APIs) from the acidic environment of the stomach and ensure targeted drug release in the intestine, where absorption is optimal. By preventing premature degradation of APIs, EC pellets play a crucial role in improving drug stability, bioavailability, and therapeutic performance. Enteric-Coated pellets are widely used in developing modified-release formulations, enabling pharmaceutical companies to create patient-friendly dosage forms with enhanced safety and efficacy. They are especially suitable for drugs that are unstable in gastric acid, irritant to the stomach lining, or require release in a specific intestinal region.

About EC Products

Our Enteric-Coated (EC) Pellets are manufactured using advanced coating technologies and high-performance excipients to ensure precise and predictable drug release. We focus on delivering uniform particle size distribution, accurate API loading, and robust mechanical stability, which guarantees consistency across batches.

By leveraging fluid bed coating, layering, and extrusion-spheronization techniques, we create pellets that withstand gastric conditions while ensuring release at the desired intestinal pH. This makes our EC pellets highly suitable for a wide variety of APIs and therapeutic classes, including proton pump inhibitors (PPIs), antibiotics, anti-inflammatory agents, and cardiovascular drugs.

With a strong emphasis on global regulatory compliance (EU,SFDA,WHO GMP standards), we ensure that our EC pellets meet the stringent quality requirements of regulated and semi-regulated markets. Our expertise lies not only in standard formulations but also in customized development to align with market needs, therapeutic goals, and brand differentiation strategies.

Key Features

Advanced Coating

Ensures targeted intestinal drug release.

Drug Stability

Protects APIs from acidic degradation.

Controlled Release

Uniform drug release ensuring reliable bioavailability

Formulation Flexibility

Compatible with capsules, tablets, and sachets.

Quality Standards

Manufactured under cGMP and international guidelines.

Uniformity

Maintains accurate API loading and particle consistency.

EC Product Portfolio

Product Name	Percentage Available	Therapeutic Usage
Aspirin	40% / 65%	Cardiovascular
Choline Fenofibrate	60%	Lipid Regulator
Dexlansoprazole DR	17% / 20% / 22.5% / 23% / 25%	Anti-ulcerant
Dexlansoprazole DDR	17% / 20% / 22.5% / 23% / 25%	Anti-ulcerant
Duloxetine HCl	9% / 12% / 17% / 20% / 25%	Anti-depressant
Esomeprazole Mg	8.5% / 22.5%	Anti-ulcerant
Omeprazole	23.5%	Anti-ulcerant
Pancreatin (Veg/Por)	60% / 70%	Digestive Enzyme
Pantoprazole Sodium	16% / 20% / 22.5%	Anti-ulcerant
Rabeprazole	12% / 15% / 20%	Anti-ulcerant